Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialPadmanee Sharma, Matthew D. Galsky, Margitta Retz et al.|The Lancet Oncology|2017Cited by 1.8k
PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.Daniel A. Vaena, James K. Schwarz, Jorge Chaves et al.|Journal of Clinical Oncology|2018Cited by 3
Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results.Samuel A. Funt, Rohit K. Jain, Mayank Rao et al.|Journal of Clinical Oncology|2024Cited by 2